Zydus Lifesciences , a prominent pharmaceutical company, has reported a significant increase in its financial performance for the second quarter of the fiscal year. The company's results showcase strong growth and improved profitability.

Key Financial Highlights

Revenue and Profitability Surge

Zydus Lifesciences reported a robust quarterly performance with revenue rising to ₹6,100.00 crore from ₹5,240.00 crore in the same period last year, marking a significant year-over-year increase of 16.41%. This impressive growth in revenue underscores the company's strong market position and effective business strategies.

The company's EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) saw a substantial increase to ₹2,015.00 crore compared to ₹1,460.00 crore in the same period last year, representing a remarkable 38.01% growth. This significant improvement in EBITDA reflects enhanced operational performance and effective cost management strategies.

Operational Performance

Zydus Lifesciences demonstrated improved operational efficiency in the second quarter:

• EBITDA Margin expanded to 32.92% from 27.91% year-over-year, indicating a strong 5.01 percentage point improvement. This expansion in margin highlights the company's ability to enhance profitability while growing its revenue.

Fundraising Plan

In a significant development, the board of Zydus Lifesciences has approved a fundraising plan of up to ₹5,000.00 crores through various securities. This decision is subject to shareholder and regulatory approvals. The fundraising initiative could provide the company with additional capital to support its growth strategies, research and development efforts, and potential expansion plans.

Market Position and Outlook

The strong financial results reflect Zydus Lifesciences' robust market position and effective business strategies. The company's ability to significantly increase its revenue and profitability amidst a competitive pharmaceutical landscape is noteworthy.

As Zydus Lifesciences continues to focus on innovation, research and development, and expanding its product portfolio, the company appears well-positioned for sustained growth in the coming quarters. The approved fundraising plan further strengthens its financial position and may support future growth initiatives.

Note: All financial figures are in Indian Rupees (₹) and are on a consolidated basis.

Zydus Life Sciences , a prominent player in the pharmaceutical industry, has achieved a significant milestone in its manufacturing capabilities. The company recently announced that its SEZ-II manufacturing facility in Ahmedabad has successfully passed a U.S. Food and Drug Administration (FDA) inspection with zero observations.

Inspection Details

The FDA conducted a Pre-Approval Inspection (PAI) at the Zydus SEZ-II manufacturing facility in Ahmedabad from August 11-14, 2025. The inspection concluded with the facility receiving a 'No Action Indicated' (NAI) classification, indicating that it meets all regulatory standards.

Key Highlights

• Inspection Period: August 11-14, 2025
• Inspection Type: Pre-Approval Inspection (PAI)
• Result: Zero observations
• Classification: No Action Indicated (NAI)
• Outcome: Establishment Inspection Report (EIR) received

The receipt of the Establishment Inspection Report (EIR) confirms the successful completion of the inspection process, marking a crucial achievement for Zydus Life Sciences in maintaining high-quality manufacturing standards.

Recent Developments

This approval comes on the heels of other positive developments for Zydus:

1. Budesonide Approval: On November 4, 2025, Zydus received tentative approval from the USFDA for Budesonide delayed-release capsules, 4 mg. This medication is indicated for mild to moderate active Crohn's disease.

2. Manufacturing Capabilities: The Budesonide capsules will be produced at the same SEZ-II facility in Ahmedabad that received the recent FDA approval.

3. ANDA Portfolio: As of September 30, 2025, Zydus has 425 approvals and has filed 487 Abbreviated New Drug Applications (ANDAs) since the commencement of the filing process in FY 2003-04.

The successful FDA inspection and recent drug approval underscore Zydus Life Sciences' commitment to maintaining high-quality manufacturing processes and expanding its product portfolio in the U.S. market.

Zydus Life Sciences - Recent Milestones

These developments highlight Zydus Life Sciences' ongoing efforts to strengthen its position in the global pharmaceutical market through regulatory compliance and product innovation.